Clearside Biomedical/$CLSD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Clearside Biomedical
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Ticker
$CLSD
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
32
ISIN
US1850631045
Website
CLSD Metrics
BasicAdvanced
$47M
-
-$0.41
2.06
-
Price and volume
Market cap
$47M
Beta
2.06
52-week high
$1.44
52-week low
$0.32
Average daily volume
440K
Financial strength
Current ratio
3.185
Quick ratio
3.026
Long term debt to equity
-116.402
Total debt to equity
-116.402
Interest coverage (TTM)
-2.58%
Profitability
EBITDA (TTM)
-25.624
Gross margin (TTM)
89.45%
Net profit margin (TTM)
-818.60%
Operating margin (TTM)
-687.51%
Effective tax rate (TTM)
-2.38%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-54.08%
Return on equity (TTM)
91.00%
Valuation
Price to revenue (TTM)
12.083
Price to book
-1.01
Price to tangible book (TTM)
-1.01
Price to free cash flow (TTM)
-1.927
Free cash flow yield (TTM)
-51.91%
Free cash flow per share (TTM)
-31.24%
Growth
Revenue change (TTM)
-55.47%
Earnings per share change (TTM)
-25.40%
3-year revenue growth (CAGR)
-49.88%
3-year earnings per share growth (CAGR)
562.85%
10-year earnings per share growth (CAGR)
-24.53%
What the Analysts think about CLSD
Analyst ratings (Buy, Hold, Sell) for Clearside Biomedical stock.
CLSD Financial Performance
Revenues and expenses
CLSD Earnings Performance
Company profitability
CLSD News
AllArticlesVideos
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
GlobeNewsWire·1 day ago
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
GlobeNewsWire·1 month ago
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Clearside Biomedical stock?
Clearside Biomedical (CLSD) has a market cap of $47M as of July 18, 2025.
What is the P/E ratio for Clearside Biomedical stock?
The price to earnings (P/E) ratio for Clearside Biomedical (CLSD) stock is 0 as of July 18, 2025.
Does Clearside Biomedical stock pay dividends?
No, Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Clearside Biomedical dividend payment date?
Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders.
What is the beta indicator for Clearside Biomedical?
Clearside Biomedical (CLSD) has a beta rating of 2.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.